T-follicular helper (Tfh) cells differentiate through a multistep process, culminating in germinal center (GC) localized GC-Tfh cells that provide support to GC-B cells. T-follicular regulatory (Tfr) cells have critical roles in the control of Tfh cells and GC formation. Although Tfh-cell differentiation is inhibited by IL-2, regulatory T (Treg) cell differentiation and survival depend on it. Here, we describe a CD25
− subpopulation within both murine and human PD1
+ Tfr cells. It is preferentially located in the GC and can be clearly differentiated from CD25 + non-GC-Tfr, Tfh, and effector Treg (eTreg) cells by the expression of a wide range of molecules. In comparison to CD25 + Tfr and eTreg cells, CD25 − Tfr cells partially down-regulate IL-2-dependent canonical Treg features, but retain suppressive function, while simultaneously upregulating genes associated with Tfh and GC-Tfh cells. We suggest that, similar to Tfh cells, Tfr cells follow a differentiation pathway generating a mature GC-localized subpopulation, CD25
− Tfr cells.
Treg cell | T-follicular regulatory cell | Tfr cell | germinal center | Tfh cell T -follicular helper (Tfh) cells have a critical role in the formation and maintenance of germinal center (GC) reactions responsible for the production of high-quality antibodies (1) . Tfh cells differentiate in a multistage process beginning with contact with dendritic cells, which provide them with IL-6 and ICOS-ligand, allowing their up-regulation of the lineage-defining transcription factor BCL6 (2) (3) (4) . This process leads to down-regulation of chemotactic receptors (CCR7 and PSGL1) responsible for maintaining the cells in the T-cell zone and up-regulation of CXCR5, which recognizes CXCL13, enabling the cells to travel to the T/B border. Once the pre-Tfh cells contact cognate B cells and receive further stimulation, they fix the Tfh gene program that allows some Tfh cells to enter the GC and become BCL6 hi PD1 hi CXCR5
hi IL-4 and IL-21, producing GC-Tfh cells (1) .
Foxp3-expressing regulatory T (Treg) cells are vital for the maintenance of immune tolerance and homeostasis (5) . Loss of Foxp3 expression, in mice or humans, or depletion of total Treg cells leads to spontaneous expansion of GCs and Tfh cells, resulting in the production of autoantibodies and hyperproduction of IgE (6) . Treg cells are able to become T-follicular regulatory (Tfr) cells by coopting the Tfh transcriptional program, including the expression of BCL6. This program allows them to access the follicles and GCs, and to provide in situ suppression of antibody production (7) (8) (9) (10) . However, it is not clear if there is a highly differentiated subset of Tfr cells, equivalent to GC-Tfh cells, in GCs.
We initially identified Treg cells by their high-level expression of the α-chain of the IL-2 receptor (CD25) (11) . IL-2 is important for both the thymic production of Treg cells and their peripheral maintenance because IL-2 signaling via CD25 and STAT5 is essential for Treg proliferation and survival (12) . Further, the differentiation of highly activated CD103 + KLRG1 + effector Treg (eTreg) cells is dependent on the expression of BLIMP-1 (13) . Conversely, Tfh cells are CD25 lo and BCL6 is known to be a reciprocal regulator of BLIMP-1 (2) . As a result, Tfh cells are directly inhibited by IL-2/STAT5-driven induction of BLIMP-1 expression (14, 15) . In addition, Tfr cells themselves have been described to express BLIMP-1, but its deletion causes their expansion, suggesting that BLIMP-1 acts to inhibit their formation (10) , whereas loss of BCL6 results in increased expression of BLIMP-1 by Treg cells (7) . This finding raises the question of how Tfr cells are able to balance these seemingly contradictory signals. Here, we describe that Tfr cells can be subdivided into CD25
+ and CD25
− subpopulations and that the CD25 − Tfr cells lose part of their IL-2-dependent Treg identity in exchange for enhanced expression of BCL6 and other Tfh-related genes, which, in turn, allows them to travel to the GC. As such, we identify CD25
hi Treg cells as an IL-2-independent subpopulation of eTreg cells present in both mice and humans.
Results

Identification of CD25
− Tfr Cells. To identify Tfr cells in the lymph nodes (LNs) of vaccinated mice, we used a gating structure beginning with CD3 
PD1
+ Treg cells had a bimodal staining pattern of CD25 in both our own data and other published data (10) (Fig. 1A) , allowing us to identify CD25 − Tfr and CD25 + Tfr cells. The proportion of CD25 − Tfr cells varied by lymphoid organ, with 24 ± 1% in the draining LNs, 57 ± 2% in the spleen, and 73 ± 4% in the Peyer's patches 7 d after vaccination (mean ± SEM; Fig. S1A ). Naive and effector conventional T (nTconv and eTconv, respectively) cells were defined as Foxp3 − Tfr cells in the spleen and LNs, whereas the Peyer's patches had a constant population of these cells unaffected by vaccination. To supplement this manual gating, we also used Automatic Classification of Cellular Expression by Nonlinear Stochastic Embedding (ACCENSE), a tool that uses a dimensionality reduction technique, t-distributed stochastic neighbor embedding, which allows the visualization of multiple parameters in two dimensions and is useful in the identification of novel subpopulations (16) . Here, we took total CD4 T cells from the Peyer's patches and mapped them by expression of PD1, BCL6, CXCR5, Foxp3, and CD25. Treg cells could be seen to form two distinct "islands," one CD25
− and the other CD25
hi Treg cells could be seen to be clustering primarily on the CD25 − island, confirming the identification of these cells as a distinct population (Fig. S1B ).
Because the border between Tfr and non-Tfr cells was indistinct, we also used an approach of sectioning CD44 (Fig. 1B) . We then carried out time course experiments to investigate the formation of these cells. We found that the ratio of Tfh cells among CD4 + T cells peaked at day 7 before resolving, but that CD25 + Tfr cells and GCs peaked at day 14 before resolving (Fig. 1C) . The highest percentage of CD25 − Tfr cells coincided with the peak of GC formation at day 14. A similar pattern was seen when data were represented as cells per 100,000 lymphocytes (Fig. S1C) .
The transcription factor BCL6 is essential for the formation of Tfh and Tfr cells (2-4, 7, 10 
CD62L
− Treg cells, were completely abolished in BCL6 CD4 cKO mice, as were Tfr cells (Fig. 1D) Fig. 2A and Fig. S2 ), and lower CCR7 and PGSL1, although both lacked IL-21 expression. ICOS and TIGIT were more highly expressed by both CD25 − Tfr and CD25 + Tfr cells than either Tfh or Treg cells ( Fig. 2A and Fig. S2 ).
In addition to the near-total loss of CD25, CD25 − Tfr cells showed reduced expression of Foxp3, Helios, CD103, KLRG1, GITR, and BLIMP-1 ( Fig. 2 A and B and Fig. S2 ). However, in 
CD103
+ Treg cells (17) . We found that eTreg cells expressed KLRG1 and CD103 and that CD25 + Tfr cells maintained CD103 but had reduced KLRG1 expression, whereas CD25 − Tfr cells were double negative, similar to nTreg cells ( Fig. 2C and Fig. S2 ). One possible explanation for lower KLRG1, CD103, and BLIMP-1 by CD25 − Tfr cells is reduced activation status, even within the CD44 +
CD62L
− gate. We found, however, that CD25 − Tfr cells were Ki-67 hi and BCL2 lo ( Fig.  2A and Fig. S2 ), suggesting that they were highly proliferative, apoptosis-prone effector cells and could not be considered at a lower activation status than CD25 + Tfr or eTreg cells. (18) , whereas low levels of CCR7 and PGSL-1 also aid their localization to the follicle/GC (19, 20) . We hypothesized that because CD25 − Tfr cells were CXCR5 hi PD1 hi CCR7 lo PGSL-1 lo , they might be preferentially localized in GCs. On examination of spleen sections by confocal microscopy, we found that in the T-cell zone of unvaccinated mouse spleens, the majority of Foxp3-expressing cells also expressed CD25, although this expression was reduced in B-cell follicles (Fig.  3A) . Following vaccination and formation of GCs, we again observed that most Foxp3
+ Treg cells in the T-cell zone expressed CD25, with reduced expression in the follicles and only a small minority of Foxp3 + cells in the GCs expressing CD25 ( Fig. 3 B and C). Similar to our earlier results (Fig. S1A ), we also found that CD25 expression was lower in the spleen than in the LNs (Fig. 3C ). 
GITR
− eTconv, (Fig. S3A ). In addition, analysis of a list of known Tfh genes, such as Sphingosine-1-phosphate receptor 2 (S1PR2), a molecule previously demonstrated to be important for the retention of Tfh in the GC, demonstrated a similar expression pattern (21) (Fig. S3B ). To confirm this finding, we performed gene set enrichment analysis (GSEA) using the top 250 Tfh up-regulated and Treg up-regulated genes from our previous DE list as the gene set database. CD25
− Tfr cells were significantly enriched for Tfh up-regulated genes, whereas CD25 + Tfr cells were significantly enriched for Treg up-regulated genes (Fig. 4C ). Further analysis also demonstrated that CD25 − Tfr cells were significantly enriched for genes previously identified as up-regulated by BCL6 hi GC-Tfh cells in comparison to CD4 T cells (22) (Fig. S3C) .
Analysis of a wide range of Treg suppressive molecules (e.g., CTLA-4, TIGIT, TGF-β1), and other key Treg markers demonstrated that CD25 − Tfr cells retained the expression of most known suppressive molecules (Fig. 4D ). Only Il10, GrzB (encoding the protein Granzyme B), and Itgae (encoding the protein CD103) were DE (P < 0.01, ≥ twofold change) between CD25 + Tfr and CD25 − Tfr cells. The visual impression given by the heat maps was then further confirmed by principal component analysis ( Fig. 4E ) and Euclidian distance (Fig. S3D) shifted toward Tfh cells, whereas CD25 + Tfr cells were closer to eTreg and nTreg cells. More precisely, we found that the Euclidian distances to the Tfh and eTreg gene expression signatures were almost equidistant for CD25 − Tfr cells, confirming that these cells are equally poised between these fates (Fig. 4F) . Full lists of differentially up-regulated genes between CD25 − Tfr, CD25 + Tfr, eTreg, and Tfh cells are provided in Dataset S1.
Although we noted the up-regulation of some myeloid-related genes in the Tfr subpopulations, it could be attributed to some contamination due to sorting these rare cells. However, despite this caveat, we believe the results are still conclusive.
CD25
− Tfr Cells Are Stably Foxp3-Expressing Suppressive Treg Cells.
Gene expression results suggested that CD25 − Tfr cells might retain suppressive Treg characteristics. To confirm this point, we used an in vitro assay to examine the ability of Treg/Tfr cells to suppress the up-regulation of IgG1 by B cells in culture with Tfh cells. Here, we found that nTreg, eTreg, CD25
+ Tfr, and CD25
−
Tfr cells all possessed the ability to suppress B-cell switching to IgG1 (Fig. S4A ) and reduced IgG1 concentrations in the supernatants of the same cultures (Fig. 5A) . We also used Tfh cells as a negative control for suppressive function. Here, we found that both CD25 + Tfr and CD25 − Tfr cells retained their suppressive function, although this suppressive function was slightly reduced in CD25 − Tfr cells (Fig. S4B ). How CD25
− Tfr cells down-regulate CD25 expression is another critical point. In Tfh cells, the transcription factor ASCL2 has been described as both enhancing CXCR5 expression and downregulating CD25 in Foxp3
− effector T cells (23) . CD25 − Tfr cells showed increased expression of ASCL-2 in comparison to other Treg cells (Fig. S3B) , suggesting that ASCL2 may play a role in their loss of CD25 expression. To address this possibility, we transfected naive CD25 +
CD62L
+ Treg cells with retrovirus containing either empty vector (EV) or ASCL2. We found that ASCL2-transfected cells, but not EV-transfected cells, both marked by NGF-receptor positivity, substantially up-regulated CXCR5 (Fig. 5B) . Additionally, EV cells did not show a clear change in CD25 expression, whereas ASCL2-transfected cells showed down-regulation of CD25 expression.
IL-2 is well described as a critical factor for the survival and stability of Treg cells, and some CD25-deficient Treg cells have been reported to be unstable transient expressers of Foxp3 (24) . This finding poses an important question of how CD25
− Tfr cells are able to survive without IL-2 signaling and whether they are stable Foxp3-expressing cells. In the absence of IL-2, IL-4 has been demonstrated to be able to sustain both Treg proliferation and the suppressive activity of Treg cells (25, 26) . Additionally, IL-4 is produced by GC-Tfh cells, suggesting that it would be available in the GC (27) . We therefore cultured purified Tfr cells in vitro with anti-CD3/CD28 Dynabeads, with/without IL-2 or IL-4, to test their survival and stability of Foxp3 expression, and we found that CD25 − Tfr and CD25 + Tfr cells were able to retain Foxp3 expression at least as well as nTreg and eTreg cells (Fig. 5C, Left) . Tfh cells did not express Foxp3 in these conditions. Because IL-6 reportedly destabilizes Foxp3 expression (28) but has a role in Tfh formation, IL-6 was added to cell cultures to test the stability of the Treg subsets in adverse conditions. A partial loss of Foxp3 expression was seen; however, the most affected subset was nTreg cells. This finding suggests that CD25
−
Tfr and CD25
+ Tfr cells are both firmly imprinted into the Tregcell lineage (Fig. S4C) . In the absence of cytokine support, nTreg, eTreg, CD25
+ Tfr, and CD25 − Tfr cells all survived poorly. The addition of either IL-2 or IL-4 was able to restore survival, although IL-2 was more effective (Fig. 5C, Right) .
During in vitro culture, CD25 − Tfr cells rapidly regained expression of CD25 in the presence or absence of IL-2 or IL-4 ( Fig.  5C ), despite having been confirmed as CD25 lo after sorting (Fig.  S4D) . CD25 up-regulation was also seen by Tfh cells themselves, suggesting that once removed from their specialized in vivo microenvironment, both Tfh and Tfr cells may fail to maintain low CD25 expression. Moreover, when CD25 − Tfr and nTconv cells were transferred into athymic nude mice, the CD25 − Tfr cells were largely converted to CD25 + CXCR5 − Treg cells (Fig. S4E ). Another gold standard marker of Treg-cell lineage is their epigenetic status. Assessing sorted cells for demethylation, we found that CD25
− Tfr and CD25 + Tfr cells both had a demethylated Foxp3 CNS2 region (29) (Fig. 5D ). This finding is of particular relevance because Foxp3 CNS2 has been described to be responsible for maintaining the stability of Foxp3 expression in the absence of IL-2 and the presence of inflammatory cytokines, such as IL-4 (30, 31) .
A number of investigative groups have addressed the possibility that Tfr cells are derived from Tfh cells and have concluded that they are not (7, 8, 10) , at least in the absence of incomplete Freund's adjuvant (IFA) (32 
CD25
− Tfr cells (Fig. 5E) , 
Zero cross at 5549 Zero cross at 5549 Fig. 4 . RNA-Seq of CD25 − Tfr cells. Mice were vaccinated with NP-Ova in alum, and dLNs were taken at day 7. A total of 1 × 10 4 cells were sorted by Becton Dickinson (BD) FACSAria-SORP before RNA-Seq. RNA was extracted using RLT buffer (Qiagen), and then subjected to library preparation using the Quartz-Seq protocol and sequenced by Ion Proton (Life Technologies). Heat maps, principal component analysis, and Euclidean distance analysis were produced using R software. Differential gene expression analysis was performed in R by TCC/DEseq2. Genes with a false discovery rate of <0.01 and a fold change of ≥2 were considered DE. demonstrating that CD25 + nTreg cells were able to give rise to CD25 − Tfr cells. As before, the proportion of these cells varied by lymphoid organs, with the spleen and Peyer's patches having higher proportions of CD25 − Tfr cells. Loss of CD25 expression was specific to Tfr cells because eTreg cells had significantly smaller fractions of CD25 − cells (Fig. 5E ). CD45.2
−
Foxp3
+ Foxp3-Gfp − cells (which express Foxp3 protein but lack the Foxp3-Gfp gene) converted from transferred Tconv cells were largely absent from both CD25 + Tfr and CD25 − Tfr cells. (Fig. S4F ).
IL-2 Antagonizes the Formation and Maintenance of CD25
− Tfr Cells.
To assess the impact of the loss of IL-2 on Tfr-cell formation, we examined IL-2-deficient mice. Here, we found that the proportions of Treg cells were significantly reduced (Fig. S5A) , coinciding with large-scale spontaneous formation of Tfh cells and GCs (Fig. S5B) . Of the remaining Treg cells, a large proportion were CXCR5 + PD1 + CD25 − Tfr cells, confirming their lack of dependence on IL-2 signaling (Fig. S5C) . Although homozygous IL-2 KO ( −/− ) mice suffer from severe inflammation, heterozygous ( +/− ) mice were healthy at the age used in these experiments and showed similar, if less dramatic, results. Although the numbers of Tfr cells were very low in unvaccinated wild-type or heterozygous mice, we assessed Tfr cells in the Peyer's patches and found that the percentage of CD25 − Tfr cells was increased in both the IL-2 KO −/− and IL-2/KO +/− mice (Fig. S5D ). In addition, in vivo IL-2 blockade by antibody enhanced the formation of CD25 − Tfr and Tfh cells while reducing Treg-cell frequencies (Fig. S5 E-G) .
To address the effect of adding IL-2, we used IL-2/anti-IL-2 complexes that have been demonstrated to expand Treg cells efficiently in vivo (33) . Because the spleen contained a relatively large proportion of CD25 − Tfr cells (Fig. S1 ), we used the spleen for assessing the effects of IL-2/anti-IL-2 complexes and found that Foxp3 + cells rapidly expanded in a dose-dependent manner over the course of a week, whereas Tfr cells were reduced (Fig. S6 A and B) . The remaining Tfr cells became CD25 + (Fig. S6 A and B) , although they also lost expression of BCL6 (Fig. S6C) . CD25
− Tfr cells were reduced in total number as well as proportion, demonstrating that this result was not simply a dilution effect due to excessive eTreg-cell proliferation (Fig. S6C) . Some of these effects may be indirect due to the impact of IL-2 on Tfh cells and GCs, which were both reduced by the treatment (Fig. S6C) . In the Peyer's patches, CD25
− Tfr cells were also significantly reduced in frequency, but the reduction in number was not significant (P = 0.08), whereas GCs and Tfh were retained, suggesting that the effects could not be ascribed to loss of GCs but that preferential expansion of CD25 + Treg cells may be a factor (Fig. S6 D and E) . We also took advantage of a published dataset examining CD25 hi and CD25 lo Treg cells from wild-type mice, as well as Treg cells from IL-2 −/− mice with/without i.p. injection of IL-2. As predicted by our results, CD25 lo Treg cells had enhanced expression of Cxcr5, Bcl6, and Pdcd1 (Fig. S6F) . Furthermore, Treg cells from IL-2-deficient mice had similar up-regulation of these genes, and this up-regulation was rapidly diminished by IL-2 treatment, which caused down-regulation of Cxcr5, Bcl6, and Pdcd1 but up-regulation of Il2ra and Selplg (PSGL-1) (12) (Fig. S6F Additionally, GSEA analysis comparing RNA-Seq data from our CD25 − Tfr and CD25 + Tfr cells with the RNA-Seq data of Treg cells from IL2Rβ KO mice demonstrated that CD25 + Tfr cells were significantly enriched for the genes down-regulated by IL2Rβ KO Treg cells compared with wild-type Treg cells (34) (Fig. S6G) (Fig. 6A ). The cTfr cells were then sorted (CD127 lo CD25
+ was used in place of Foxp3) and further confirmed as bona fide Treg cells with demethylation of Foxp3 CNS2 (Fig. 6B) .
In comparison to eTreg cells, cTfr cells had reduced expression of Foxp3, and the previously identified eTreg marker CD15s (35) (Fig. 6C) . However, although expression was reduced in comparison to eTreg cells, it was increased in comparison to nTreg cells. There was not a clear CD25 − population, but the level of CD25 expression was significantly decreased in cTfr cells in comparison to both eTreg and nTreg cells, suggesting that in contrast to eTreg cells, Tfr down-regulated CD25 on activation. We also assessed markers of activation and proliferation (HLA-DR and Ki-67) and found that cTfr cells had low levels of these markers in comparison to eTreg cells (Fig. S7A) . Because we have previously demonstrated that positivity for CD15s and high levels of Foxp3 hi expression are associated with Treg-suppressive function (36) , this finding raised the question of whether cTfr cells retained their suppressive function. In vitro, both eTreg and cTfr cells lacked any helper function to support B-cell survival or antibody production (Fig. S7 B and C) but were able to suppress in vitro B-cell activation by Tfh cells, blocking formation of CD20 lo CD38 hi plasma cells and the resulting IgG production ( Fig. 6D and Fig. S7C ). Additionally, in terms of ability to suppress T-cell proliferation, we found that in vitro, cTfr cells possessed suppressive function similar to the suppressive function of nTreg cells: higher than Tfh cells but less than highly activated eTreg cells (Fig. S7D ). To provide a more detailed assessment of cTfr cells, we then performed RNA-Seq. Similar to the results seen in mice (Fig. 4F and Fig. S3D ), we found that cTfr cells had levels of overall Euclidean distance of their gene expression signature similar to both eTreg and Tfh cells, although hierarchical clustering revealed that they were slightly closer to Tfh cells than eTreg cells, suggesting an intermediate genotype (Fig.  6E) . This finding was also confirmed by heat maps of the 25 most up-regulated and down-regulated genes from Tfh to eTreg cells, with cTfr cells proven to be intermediates (Fig. 6F and Dataset S2). To explore the unique gene expression profile of cTfr cells further, fold change and expression of all genes between cTfr and Tfh cells (Fig. 6G, Left) or between cTfr and eTreg cells (Fig. 6G , Right) were plotted with DE genes [log 2 -fold change >1, q value (adjusted P) <0.05] highlighted in red. In comparison to Tfh cells, the cTfr UP signature was characterized by many of the genes associated with Treg function, such as Foxp3, IL2RA (CD25), and PRMD1 (Blimp-1); in contrast, few genes were down-regulated. In comparison to eTreg cells, the cTfr UP signature was characterized by gain of Tfh-related molecules and transcription factors, such as CXCR5, TCF7, and POU2AF1. We have previously demonstrated that POU2AF1 is up-regulated in blood Tfh cells, particularly the highly active CXCR3
+ subset (37) . Here, we found that POU2AF1 was in the UP signature of cTfr (Fig. 7C and Fig. S7E ). We supplemented manual gating with ACCENSE, using CXCR5, PD1, BCL6, and CD25 to map Foxp3 + Helios + -gated cells, and then K-means clustering to identify separate regions automatically (Fig. S7F) − Tfr cells to be unambiguously identified as a Treg subpopulation. It is also important to note that in human tonsils, CD25
− Tfr cells are the only Foxp3-expressing population that expresses significant amounts of BCL6.
We noted that the ratio of CD25-expressing Tfr cells varied between lymphoid organs. This variation may be due to availability of STAT5 signaling, because a lower proportion of Treg cells are pSTAT5 + in the spleen than in the LNs (38) . IL-2-driven pSTAT5 
BCL6
hi phenotype associated with GC-Tfh cells being enriched for, but not exclusive to, GC localized cells, as confirmed by several microscopy studies (18, 40) . Additionally, GC-Tfh cells are capable of cycling in and out of the GCs, so they may not be localized in the GC at all times (18) . Further study is needed to assess if Tfr cells also cycle in this manner.
It has recently been demonstrated that CD25 is downregulated by a subset of CD103 + , KLRG1 Our results suggest that the antagonism between BLIMP-1 and BCL6 may cause two main differentiation paths for eTreg cells, that is, a classical IL-2-dependent path defined by BLIMP-1 and characterized by expression of CD25, KLRG1, CD103, Granzyme B, and IL-10, and a separate IL-2-antagonized path defined by BCL6 and characterized by CXCR5, TIGIT, ICOS, BTLA, and PD1. This finding adds a layer of complexity when assessing the phenotype of Treg cells, because assessment of total Treg cells may fail to differentiate between changes in activation status and subpopulations. For example, expression levels of CD103 could be determined by either overall changes to Treg activation status or underlying shifts in compositions of eTreg subpopulations that do or do not favor CD103. Because simultaneous identification of all Treg subpopulations is impractical, characterization and use of subpopulation-independent Treg activation markers, such as Ki-67, CD44, and CTLA-4, and loss of CCR7 and CD62L may potentially be more appropriate for a broad overview of Treg activation status.
Tfr cells maintain a delicate balance between incompatible aspects of their Tfh and Treg identities. We propose that in both mice and humans, CD25
− Tfr cells down-regulate CD25 to insulate themselves from IL-2 signaling that would otherwise lead to up-regulation of BLIMP-1 and prevent high-level expression of BCL6 and other Tfh factors. This down-regulation allows the cells to traffic to the inner follicles and GCs. Although some aspects of Treg gene expression are lost or partially down-regulated, key features, such as Foxp3, GITR, Helios, and CTLA-4 expression, are retained. This finding demonstrates that Tfr cells display high levels of flexibility to adopt large portions of the Tfh gene signature while still retaining their fundamental identity as Treg cells.
Materials and Methods
Detailed methods can be found in Supporting Information.
Murine Sample Preparation. BALB/c and C57BL/6 mice were obtained from CLEA Japan, Inc. and maintained under specific pathogen-free conditions. All experiments used mice on a C57BL/6 background except where noted. BCL6 flox, IL-2 −/− , BLIMP-1 reporter, Foxp3 fusion protein DTR-GFP (FDG), Foxp3-Gfp eFox, and IL-21 reporter mice have already been described (45) (46) (47) (48) (49) .
Mice were killed by CO 2 , and draining LNs (inguinal), spleens, and/or Peyer's patches were removed by dissection before disaggregation by grinding with frosted glass slides and suspension in RPMI media and 2% FCS. 
